<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353234</url>
  </required_header>
  <id_info>
    <org_study_id>DDR-001</org_study_id>
    <nct_id>NCT02353234</nct_id>
  </id_info>
  <brief_title>Bioavailability of Phenolic Compounds in Bread</brief_title>
  <official_title>Bioavailability of Phenolic Compounds in Wholegrain Bread Compared With White Bread Enriched With Aleurone Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Parma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The consumption of wholemeal cereals has been associated with the reduction of several
      chronic diseases. The mechanisms behind these protective effects may be linked, besides
      dietary fiber and micronutrients, to an increased intake of phenolic compounds, mainly,
      hydroxycinnamates contained in the bran. Among bran fractions, aleurone usually contains the
      highest concentration of ferulic acid, principally contained as monomeric form and diferulic
      acid esters linked to arabinoxylans, representing the most relevant subclasses. The aim of
      the study was to evaluate the absorption of hydroxycinnamates by measuring the urinary
      excretion of phenolic metabolites in humans fed with two different kind of a commercial
      bread, as wholegrain bread and a white bread enriched with aleurone fraction. Moreover, the
      pharmacokinetics of the main phenolic compounds was also evaluated by measuring the
      circulating metabolites in plasma samples.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phenolic compound bioavailability in wholegrain bread compared with bread enriched with aleurone fraction (urine samples will be filtered and diluted and phenolic compound metabolites will be identified)</measure>
    <time_frame>0h; 0-3h; 3-6h; 6-10h; 10-14h; 14-24h; 24-28h; 28-34h; 34-48h.</time_frame>
    <description>Volunteers will collect urine before consuming bread (T0) and for 48 hours after the consumption of the meal test, in each study arms. Urine samples will be collected and stored at -80Â°C until uHPLC/MS analysis. Prior analysis, urine samples will be filtered and diluted and phenolic compound metabolites will be identified.
Expected Metabolites:
Coumaric acid, Hydroxyphenylpropionic acid, Dihydroxyphenylacetic acid, Hippuric acid, Enterolactone, Enterodiol, Coumaric acid sulphate, Phenylpropionic acid sulphate, Vanillic acid sulphate, Hydroxyphenylpropionic acid sulphate, Ferulic acid sulphate, Dihydroferulic acid sulphate, Hydroxyphenylpropionic acid glucuronide, Ferulic acid glucuronide, Enterolactone sulphate, Enterodiol sulphate, Enterolactone glucuronide, Enterodiol glucuronide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phenolic compound pharmacokinetics in wholegrain bread compared with bread enriched with aleurone fraction (metabolites identified in Plasma samples that will be collected prior (T0) and after bread consumption in each study arms.)</measure>
    <time_frame>0h; 0.5h; 1h; 2h; 4h; 7h; 24h.</time_frame>
    <description>Plasma samples will be collected prior (T0) and after bread consumption in each study arms.
Expected Metabolites:
Coumaric acid, Hydroxyphenylpropionic acid, Dihydroxyphenylacetic acid, Hippuric acid, Enterolactone, Enterodiol, Coumaric acid sulphate, Phenylpropionic acid sulphate, Vanillic acid sulphate, Hydroxyphenylpropionic acid sulphate, Ferulic acid sulphate, Dihydroferulic acid sulphate, Hydroxyphenylpropionic acid glucuronide, Ferulic acid glucuronide, Enterolactone sulphate, Enterodiol sulphate, Enterolactone glucuronide, Enterodiol glucuronide.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Dietary Modification</condition>
  <arm_group>
    <arm_group_label>WHOLEGRAIN BREAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects feed with wholegrain bread, for which ferulic acid content has been quantified.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WHITE BREAD WITH ALEURONE - 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects feed with white bread with aleurone fraction in the same portion as wholegrain bread.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WHITE BREAD WITH ALEURONE - 8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects feed with white bread with aleurone fraction, which contains the same quantity of ferulic acid as wholegrain bread.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bread</intervention_name>
    <description>In each arm subjects consume bread</description>
    <arm_group_label>WHOLEGRAIN BREAD</arm_group_label>
    <arm_group_label>WHITE BREAD WITH ALEURONE - 4</arm_group_label>
    <arm_group_label>WHITE BREAD WITH ALEURONE - 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 18-25 kg/m2

        Exclusion Criteria:

          -  Pregnancy and breastfeeding

          -  diagnosis of celiac disease

          -  diagnosed methabolic diseases (diabetes and disorders of glycaemic control,
             hypertension, dyslipidemia)

          -  sustained use of nutritional supplements of vitamins, in particular E and C, at the
             recruitment step

          -  chronic pharmacological therapy

          -  antibiotic therapy during the last 40 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniele Del Rio, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Parma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Parma - Department of Food Science</name>
      <address>
        <city>Parma</city>
        <zip>43125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Anson NM, Selinheimo E, Havenaar R, Aura AM, Mattila I, Lehtinen P, Bast A, Poutanen K, Haenen GR. Bioprocessing of wheat bran improves in vitro bioaccessibility and colonic metabolism of phenolic compounds. J Agric Food Chem. 2009 Jul 22;57(14):6148-55. doi: 10.1021/jf900492h.</citation>
    <PMID>19537710</PMID>
  </reference>
  <reference>
    <citation>Del Rio D, Rodriguez-Mateos A, Spencer JP, Tognolini M, Borges G, Crozier A. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal. 2013 May 10;18(14):1818-92. doi: 10.1089/ars.2012.4581. Epub 2012 Aug 27. Review.</citation>
    <PMID>22794138</PMID>
  </reference>
  <reference>
    <citation>Gabrielsson J, Weiner D. Non-compartmental analysis. Methods Mol Biol. 2012;929:377-89.</citation>
    <PMID>23007438</PMID>
  </reference>
  <reference>
    <citation>Kikuzaki H, Hisamoto M, Hirose K, Akiyama K, Taniguchi H. Antioxidant properties of ferulic acid and its related compounds. J Agric Food Chem. 2002 Mar 27;50(7):2161-8.</citation>
    <PMID>11902973</PMID>
  </reference>
  <reference>
    <citation>Calani L, Ounnas F, Salen P, Demeilliers C, Bresciani L, Scazzina F, Brighenti F, Melegari C, Crozier A, de Lorgeril M, Del Rio D. Bioavailability and metabolism of hydroxycinnamates in rats fed with durum wheat aleurone fractions. Food Funct. 2014 Aug;5(8):1738-46. doi: 10.1039/c4fo00328d.</citation>
    <PMID>24977665</PMID>
  </reference>
  <reference>
    <citation>Luceri C, Giannini L, Lodovici M, Antonucci E, Abbate R, Masini E, Dolara P. p-Coumaric acid, a common dietary phenol, inhibits platelet activity in vitro and in vivo. Br J Nutr. 2007 Mar;97(3):458-63.</citation>
    <PMID>17313706</PMID>
  </reference>
  <reference>
    <citation>Mateo Anson N, Hemery YM, Bast A, Haenen GR. Optimizing the bioactive potential of wheat bran by processing. Food Funct. 2012 Apr;3(4):362-75. doi: 10.1039/c2fo10241b. Epub 2012 Feb 15. Review.</citation>
    <PMID>22336890</PMID>
  </reference>
  <reference>
    <citation>Stalmach A, Mullen W, Barron D, Uchida K, Yokota T, Cavin C, Steiling H, Williamson G, Crozier A. Metabolite profiling of hydroxycinnamate derivatives in plasma and urine after the ingestion of coffee by humans: identification of biomarkers of coffee consumption. Drug Metab Dispos. 2009 Aug;37(8):1749-58. doi: 10.1124/dmd.109.028019. Epub 2009 May 21.</citation>
    <PMID>19460943</PMID>
  </reference>
  <reference>
    <citation>Stalmach A, Steiling H, Williamson G, Crozier A. Bioavailability of chlorogenic acids following acute ingestion of coffee by humans with an ileostomy. Arch Biochem Biophys. 2010 Sep 1;501(1):98-105. doi: 10.1016/j.abb.2010.03.005. Epub 2010 Mar 11.</citation>
    <PMID>20226754</PMID>
  </reference>
  <reference>
    <citation>Truswell AS. Cereal grains and coronary heart disease. Eur J Clin Nutr. 2002 Jan;56(1):1-14. Review.</citation>
    <PMID>11840174</PMID>
  </reference>
  <reference>
    <citation>Zaupa M, Scazzina F, Dall'Asta M, Calani L, Del Rio D, Bianchi MA, Melegari C, De Albertis P, Tribuzio G, Pellegrini N, Brighenti F. In vitro bioaccessibility of phenolics and vitamins from durum wheat aleurone fractions. J Agric Food Chem. 2014 Feb 19;62(7):1543-9. doi: 10.1021/jf404522a. Epub 2014 Feb 6.</citation>
    <PMID>24450764</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Parma</investigator_affiliation>
    <investigator_full_name>Daniele Del Rio</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Phenolics</keyword>
  <keyword>Aleurone</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

